Microsoft Word 11.0.6359;Exhibit 31.1
                                  CERTIFICATION

I, Mechael Kanovsky, Ph.D., certify the following:

1.    I have reviewed this annual report on Form 10-KSB of Amazon Biotech, Inc.;

2.    Based on my knowledge, this annual report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this annual report;

3.    Based on my knowledge, the financial statements, and other financial
      included in this annual report, fairly present in all material respects
      the financial condition, results of operations and cash flows of Amazon
      Biotech, Inc. as of, and for, the periods presented in this annual report;

4.    Amazon Biotech, Inc.'s other certifying officer and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Amazon Biotech,
      Inc. and we have done the following:

      a.    such disclosure controls and procedures, or caused disclosure
            controls and procedures to be designed under our supervision, to
            ensure that material information relating to Amazon Biotech, Inc.,
            including its consolidated subsidiaries, is made known to us by
            others within those entities, particularly during the period in
            which this annual report is being prepared;

      b.    such internal control over financial reporting, or such internal
            control over financial reporting to be designed under our
            supervision, to provide reasonable assurance regarding the
            reliability of financial reporting and the preparation of financial
            statements for external purposes in accordance with generally
            accepted accounting principles;

      c.    the effectiveness of Amazon Biotech, Inc.'s disclosure controls and
            procedures and presented in this annual report our conclusions about
            the effectiveness of the disclosure controls and procedures, as of
            the end of the period covered by this report based on such
            evaluation; and

      d.    in this annual report any change in Amazon Biotech, Inc.'s internal
            control over financial reporting that occurred during Amazon
            Biotech, Inc.'s fourth fiscal quarter that has materially affected,
            or is reasonably likely to materially affect, Amazon Biotech, Inc.'s
            internal control over financial reporting; and

5.    Amazon Biotech, Inc.'s other certifying officer and I have disclosed,
      based on our most recent evaluation of internal control over financial
      reporting, to Amazon Biotech, Inc.'s auditors and the audit committee of
      the Amazon Biotech, Inc.'s board of directors:

<PAGE>

      a.    all significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect Amazon Biotech, Inc.'s ability
            to record, process, summarize and report financial information; and

      b.    any fraud, whether or not material, that involves management or
            other employees who have a significant role in Amazon Biotech,
            Inc.'s internal control over financial reporting.


November 14, 2005                              /s/ Mechael Kanovsky, Ph.D
                                               ---------------------------
                                                   Mechael Kanovsky, Ph.D.
                                                   President
                                                   (Principal Executive Officer)